Ocugen is a biotechnology company developing investigational gene therapies, biologics, and vaccines, with a primary focus on retinal diseases and blindness. Founded in 2013 by Shankar Musunuri and Uday Kompella, the company’s pipeline includes modifier gene therapy candidates for retinitis pigmentosa, Stargardt disease, and geographic atrophy, alongside a biologic candidate and inhaled vaccine programs.
Outlook Therapeutics, IncOutlook Therapeutics is a biopharmaceutical company developing and commercializing ophthalmic therapies for retinal diseases, centered on LYTENAVA™ (bevacizumab-vikg) for neovascular, or wet, age-related macular degeneration. LYTENAVA is the first and only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the United States, and is also authorized for the same use in the European Union and United Kingdom. The company is building on its clinical development experience to expand access to ophthalmic bevacizumab and pursue additional retinal-disease applications.ISELIN, NJ
OcuDyneFormed in 2013, OcuDyne is a clinical-stage medical device company developing minimally invasive therapies for age-related macular degeneration by improving blood flow to the eye. Its work grew from research linking compromised ocular perfusion with AMD progression, and its investigational OPTiC system has advanced through clinical trials in Argentina and Australia.BALTIMORE, MD
PhotoOpTxBased in Solon, Ohio, PhotoOpTx develops photobiomodulation medical devices and treatment protocols for retinal disorders, including its investigational Retilux laser therapy device for diabetic macular edema. The company’s work centers on non-pharmacological light-based approaches intended to address unmet needs in ophthalmology, with research conducted alongside organizations such as the Jaeb Center for Health Research and the DRCR Network.SOLON, OH
Galimedix Therapeutics, IncGalimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral and topical small-molecule therapies for neurodegenerative diseases of the eye and brain. Its lead candidate, GAL-101, targets misfolded amyloid beta before toxic oligomers form and is being studied as an eye drop for geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s approach also supports planned development in glaucoma and Alzheimer’s disease, with ophthalmology commercialization backed by Théa Open Innovation.KENSINGTON, MD